EMA Authorised: Somavert (pegvisomant) — Pfizer Europe MA EEIG

View source ↗

Summary

The EU has authorized Somavert (pegvisomant) for acromegaly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Somavert (pegvisomant)

Snippet

Status: Authorised. Therapeutic area: Acromegaly. MAH: Pfizer Europe MA EEIG. Decision date: 25/02/2025